{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T02:19:18Z","timestamp":1792981158555,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID 00481"],"award-info":[{"award-number":["UID 00481"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID 4501"],"award-info":[{"award-number":["UID 4501"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008382","name":"Fundo Regional para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["COMPETE2030-FEDER-00744900"],"award-info":[{"award-number":["COMPETE2030-FEDER-00744900"]}],"id":[{"id":"10.13039\/100008382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08100-6","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T11:34:51Z","timestamp":1777116891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advanced therapy medicinal product (ATMP) classification \u2013 a case study on spinal cord injury"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8012-5682","authenticated-orcid":false,"given":"L.","family":"Duarte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Castell\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7498-452X","authenticated-orcid":false,"given":"P. A. A. P.","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0082-3256","authenticated-orcid":false,"given":"B.","family":"Gago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"8100_CR1","doi-asserted-by":"publisher","DOI":"10.1159\/000524392","author":"C Priesner","year":"2022","unstructured":"Priesner C, Hildebrandt M. Advanced therapy medicinal products and the changing role of academia. S Karger AG. 2022. https:\/\/doi.org\/10.1159\/000524392.","journal-title":"S Karger AG"},{"key":"8100_CR2","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.bioactmat.2021.07.031","volume":"9","author":"L Wang","year":"2022","unstructured":"Wang L, et al. Key considerations on the development of biodegradable biomaterials for clinical translation of medical devices: With cartilage repair products as an example. Bioactive Mater. 2022;9:332\u201342. https:\/\/doi.org\/10.1016\/j.bioactmat.2021.07.031.","journal-title":"Bioactive Mater"},{"issue":"3","key":"8100_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3390\/pharmaceutics13030347","volume":"13","author":"M L\u00f3pez-Paniagua","year":"2021","unstructured":"L\u00f3pez-Paniagua M, de la Mata A, Galindo S, Bl\u00e1zquez F, Calonge M, Nieto-Miguel T. Advanced therapy medicinal products for the eye: Definitions and regulatory framework. Pharmaceutics. 2021;13(3):347. https:\/\/doi.org\/10.3390\/pharmaceutics13030347.","journal-title":"Pharmaceutics"},{"issue":"7","key":"8100_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41583-020-0314-2","volume":"21","author":"I Fischer","year":"2020","unstructured":"Fischer I, Dulin JN, Lane MA. Transplanting neural progenitor cells to restore connectivity after spinal cord injury. Nat Rev Neurosci. 2020;21(7):399\u2013414. https:\/\/doi.org\/10.1038\/s41583-020-0314-2.","journal-title":"Nat Rev Neurosci"},{"key":"8100_CR5","unstructured":"World Health Organization. Spinal cord injury. 2024. Retrieved October 12, 2024, from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/spinal-cord-injury"},{"issue":"5","key":"8100_CR6","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/nrd4621","volume":"14","author":"MP Hofer","year":"2015","unstructured":"Hofer MP, et al. Regulatory watch: Impact of scientific advice from the European Medicines Agency. Nat Rev Drug Discovery. 2015;14(5):462\u20133. https:\/\/doi.org\/10.1038\/nrd4621.","journal-title":"Nat Rev Drug Discovery"},{"issue":"7","key":"8100_CR7","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1474-4422(21)00464-6","volume":"21","author":"CM Zipser","year":"2022","unstructured":"Zipser CM, et al. Cell-based and stem-cell-based treatments for spinal cord injury: Evidence from clinical trials. Lancet Neurol. 2022;21(7):659\u201370. https:\/\/doi.org\/10.1016\/S1474-4422(21)00464-6.","journal-title":"Lancet Neurol"},{"issue":"3","key":"8100_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3892\/ETM.2013.1454","volume":"7","author":"W Ji","year":"2013","unstructured":"Ji W, Hu S, Zhou J, Wang G, Wang K, Zhang Y. Tissue engineering is a promising method for the repair of spinal cord injuries (Review). Experimental Therapeutic Med. 2013;7(3):523. https:\/\/doi.org\/10.3892\/ETM.2013.1454.","journal-title":"Experimental Therapeutic Med"},{"issue":"1","key":"8100_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41427-023-00526-4","volume":"16","author":"K Chen","year":"2024","unstructured":"Chen K, et al. Biomaterial-based regenerative therapeutic strategies for spinal cord injury. NPG Asia Mater. 2024;16(1):1\u201329. https:\/\/doi.org\/10.1038\/s41427-023-00526-4.","journal-title":"NPG Asia Mater"},{"key":"8100_CR10","doi-asserted-by":"publisher","first-page":"590549","DOI":"10.3389\/fbioe.2020.590549","volume":"8","author":"W Qu","year":"2020","unstructured":"Qu W, et al. Polymer-based scaffold strategies for spinal cord repair and regeneration. Front Bioeng Biotechnol. 2020;8:590549. https:\/\/doi.org\/10.3389\/fbioe.2020.590549.","journal-title":"Front Bioeng Biotechnol"},{"key":"8100_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bas.2025.104207","author":"K Sugai","year":"2025","unstructured":"Sugai K, Nakamura M, Okano H, Nagoshi N. Stem cell therapies for spinal cord injury in humans: A review of recent clinical research. Basal J. 2025. https:\/\/doi.org\/10.1016\/j.bas.2025.104207.","journal-title":"Basal J"},{"issue":"5","key":"8100_CR12","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1227\/NEU.0B013E31824387F9","volume":"70","author":"JH Park","year":"2012","unstructured":"Park JH, et al. Long-term results of spinal cord injury therapy using mesenchymal stem cells derived from bone marrow in humans. Neurosurgery. 2012;70(5):1238\u201347. https:\/\/doi.org\/10.1227\/NEU.0B013E31824387F9.","journal-title":"Neurosurgery"},{"issue":"11","key":"8100_CR13","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.3390\/ijms21113994","volume":"21","author":"K Yamazaki","year":"2020","unstructured":"Yamazaki K, Kawabori M, Seki T, Houkin K. Clinical trials of stem cell treatment for spinal cord injury. Int J Mol Sci. 2020;21(11):3994. https:\/\/doi.org\/10.3390\/ijms21113994.","journal-title":"Int J Mol Sci"},{"issue":"18","key":"8100_CR14","doi-asserted-by":"publisher","first-page":"14349","DOI":"10.3390\/ijms241814349","volume":"24","author":"CW Zeng","year":"2023","unstructured":"Zeng CW, et al. Advancing spinal cord injury treatment through stem cell therapy: A comprehensive review of cell types, challenges, and emerging technologies in regenerative medicine. Int J Mol Sci. 2023;24(18):14349. https:\/\/doi.org\/10.3390\/ijms241814349.","journal-title":"Int J Mol Sci"},{"key":"8100_CR15","doi-asserted-by":"publisher","unstructured":"Gao L, et al. Progress in stem cell therapy for spinal cord injury. Stem Cells Int. 2020;2853650. https:\/\/doi.org\/10.1155\/2020\/2853650.","DOI":"10.1155\/2020\/2853650"},{"issue":"36","key":"8100_CR16","doi-asserted-by":"publisher","first-page":"42429","DOI":"10.1021\/acsami.1c10818","volume":"13","author":"SH Kim","year":"2021","unstructured":"Kim SH, et al. Pastable, adhesive, injectable, nanofibrous, and tunable (PAINT) biphasic hybrid matrices as versatile therapeutic carriers. ACS Appl Mater Interfaces. 2021;13(36):42429\u201341. https:\/\/doi.org\/10.1021\/acsami.1c10818.","journal-title":"ACS Appl Mater Interfaces"},{"issue":"4","key":"8100_CR17","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1227\/neu.0000000000003180","volume":"96","author":"JS Harrop","year":"2025","unstructured":"Harrop JS, Kim KD, Okonkwo DO, Goldstein IM, Lee KS, Toselli RM. Acute implantation of a bioresorbable polymer scaffold in patients with complete thoracic spinal cord injury: A randomized controlled trial (INSPIRE 2.0). Neurosurgery. 2025;96(4):751\u201362. https:\/\/doi.org\/10.1227\/neu.0000000000003180.","journal-title":"Neurosurgery"},{"issue":"7","key":"8100_CR18","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s11427-016-5080-z","volume":"59","author":"Z Xiao","year":"2016","unstructured":"Xiao Z, et al. One-year clinical study of NeuroRegen scaffold implantation following scar resection in complete chronic spinal cord injury patients. Sci China Life Sci. 2016;59(7):647\u201355. https:\/\/doi.org\/10.1007\/s11427-016-5080-z.","journal-title":"Sci China Life Sci"},{"key":"8100_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/0963689720950637","author":"W Chen","year":"2020","unstructured":"Chen W, et al. NeuroRegen scaffolds combined with autologous bone marrow mononuclear cells for the repair of acute complete spinal cord injury: A 3-year clinical study. Cell Transplant. 2020. https:\/\/doi.org\/10.1177\/0963689720950637.","journal-title":"Cell Transplant"},{"key":"8100_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05725-3","author":"X Wang","year":"2024","unstructured":"Wang X, et al. Mesenchymal stromal cell therapies for traumatic neurological injuries. BioMed Cent. 2024. https:\/\/doi.org\/10.1186\/s12967-024-05725-3.","journal-title":"BioMed Cent"},{"key":"8100_CR21","doi-asserted-by":"publisher","first-page":"1200808","DOI":"10.3389\/fphar.2023.1200808","volume":"14","author":"S Bellino","year":"2023","unstructured":"Bellino S, La Salvia A, Cometa MF, Botta R. Cell-based medicinal products approved in the European Union: Current evidence and perspectives. Front Pharmacol. 2023;14:1200808. https:\/\/doi.org\/10.3389\/fphar.2023.1200808.","journal-title":"Front Pharmacol"},{"issue":"7679","key":"8100_CR22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature25013","volume":"551","author":"JW Fawcett","year":"2017","unstructured":"Fawcett JW, et al. Achieving regeneration and repair after spinal cord injury. Nature. 2017;551(7679):333\u201340. https:\/\/doi.org\/10.1038\/nature25013.","journal-title":"Nature"},{"key":"8100_CR23","doi-asserted-by":"publisher","DOI":"10.1089\/ten.TEA.2024.0194","author":"KJ Bradshaw","year":"2024","unstructured":"Bradshaw KJ, Leipzig ND. Applications of regenerative tissue-engineered scaffolds for treatment of spinal cord injury. Tissue Eng Part A. 2024. https:\/\/doi.org\/10.1089\/ten.TEA.2024.0194.","journal-title":"Tissue Eng Part A"},{"issue":"1","key":"8100_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40824-018-0148-4","volume":"22","author":"SG Kwon","year":"2018","unstructured":"Kwon SG, Kwon W, Lee TW, Park GT, Kim JH. Recent advances in stem cell therapeutics and tissue engineering strategies. Biomaterials Res. 2018;22(1):8. https:\/\/doi.org\/10.1186\/s40824-018-0148-4.","journal-title":"Biomaterials Res"},{"issue":"1","key":"8100_CR25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12951-023-01996-y","volume":"21","author":"Z Sun","year":"2023","unstructured":"Sun Z, et al. Recent advances in bioactive hydrogels for repairing spinal cord injury: Material design, biofunctional regulation, and applications. J Nanobiotechnol. 2023;21(1):238. https:\/\/doi.org\/10.1186\/s12951-023-01996-y.","journal-title":"J Nanobiotechnol"},{"key":"8100_CR26","doi-asserted-by":"publisher","first-page":"931800","DOI":"10.3389\/fbioe.2022.931800","volume":"10","author":"Z Lv","year":"2022","unstructured":"Lv Z, Dong C, Zhang T, Zhang S. Hydrogels in spinal cord injury repair: A review. Front Bioeng Biotechnol. 2022;10:931800. https:\/\/doi.org\/10.3389\/fbioe.2022.931800.","journal-title":"Front Bioeng Biotechnol"},{"key":"8100_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/polym13040650","author":"JM Alonso","year":"2021","unstructured":"Alonso JM, et al. Injectable hydrogels: From laboratory to industrialization. Polymers. 2021. https:\/\/doi.org\/10.3390\/polym13040650.","journal-title":"Polymers"},{"key":"8100_CR28","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.3c07419","author":"C Kwokdinata","year":"2023","unstructured":"Kwokdinata C, et al. Encapsulation of human spinal cord progenitor cells in hyaluronan-gelatin hydrogel for spinal cord injury treatment. ACS Appl Mater Interfaces. 2023. https:\/\/doi.org\/10.1021\/acsami.3c07419.","journal-title":"ACS Appl Mater Interfaces"},{"key":"8100_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1211066","author":"M Cai","year":"2023","unstructured":"Cai M, et al. Hydrogel scaffolds in the treatment of spinal cord injury: A review. Front NeuroSci. 2023. https:\/\/doi.org\/10.3389\/fnins.2023.1211066.","journal-title":"Front NeuroSci"},{"issue":"6","key":"8100_CR30","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1089\/tb.2021.0194","volume":"28","author":"K Verstappen","year":"2022","unstructured":"Verstappen K, et al. Systematic evaluation of spinal cord injury animal models in the field of biomaterials. Tissue Eng Part B: Reviews. 2022;28(6):1169\u201383. https:\/\/doi.org\/10.1089\/tb.2021.0194.","journal-title":"Tissue Eng Part B: Reviews"},{"key":"8100_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120596","author":"European Parliament and Council","year":"2017","unstructured":"European Parliament and Council. Regulation (EU) 2017\/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001\/83\/EC, Regulation (EC) 178\/2002 and Regulation (EC) 1223\/2009, and repealing Council Directives 90\/385\/EEC and 93\/42\/EEC. Official J Eur Union. 2017. https:\/\/doi.org\/10.1016\/j.biomaterials.2020.120596.","journal-title":"Official J Eur Union"},{"key":"8100_CR32","unstructured":"European Commission. Directive 2001\/83\/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Official J Eur Communities. 2001."},{"key":"8100_CR33","unstructured":"European Parliament and Council. Regulation (EC) No 1394\/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001\/83\/EC and Regulation (EC) No 726\/2004. Off J Eur Union. 2007."},{"key":"8100_CR34","unstructured":"European Medicines Agency. Reflection paper on classification of advanced therapy medicinal products. 2010. https:\/\/www.ema.europa.eu\/contact"},{"key":"8100_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2023.12.005","author":"E Olesti","year":"2024","unstructured":"Olesti E, et al. Academic challenges on advanced therapy medicinal products\u2019 development: A regulatory perspective. J Cytotherapy. 2024. https:\/\/doi.org\/10.1016\/j.jcyt.2023.12.005.","journal-title":"J Cytotherapy"},{"key":"8100_CR36","doi-asserted-by":"publisher","first-page":"757647","DOI":"10.3389\/fmed.2022.757647","volume":"9","author":"M Pizevska","year":"2022","unstructured":"Pizevska M, Kaeda J, Fritsche E, Elazaly H, Reinke P, Amini L. Advanced therapy medicinal products\u2019 translation in Europe: A developers\u2019 perspective. Front Med (Lausanne). 2022;9:757647. https:\/\/doi.org\/10.3389\/fmed.2022.757647.","journal-title":"Front Med (Lausanne)"},{"key":"8100_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/sstr.202400213","author":"JPM Sousa","year":"2024","unstructured":"Sousa JPM, et al. Magnetoresponsive anisotropic fiber-integrating hydrogels for neural tissue regeneration. Small Struct. 2024. https:\/\/doi.org\/10.1002\/sstr.202400213.","journal-title":"Small Struct"},{"key":"8100_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202400522","author":"JPM Sousa","year":"2024","unstructured":"Sousa JPM, et al. Amniotic membrane-derived multichannel hydrogels for neural tissue repair. Adv Healthc Mater. 2024. https:\/\/doi.org\/10.1002\/adhm.202400522.","journal-title":"Adv Healthc Mater"},{"issue":"17","key":"8100_CR39","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1039\/d4bm00364k","volume":"12","author":"JPM Sousa","year":"2024","unstructured":"Sousa JPM, et al. Comparative analysis of aligned and random amniotic membrane-derived cryogels for neural tissue repair. Biomaterials Sci. 2024;12(17):4393\u2013406. https:\/\/doi.org\/10.1039\/d4bm00364k.","journal-title":"Biomaterials Sci"},{"key":"8100_CR40","doi-asserted-by":"publisher","first-page":"112574","DOI":"10.1016\/j.msec.2021.112574","volume":"134","author":"IA Deus","year":"2022","unstructured":"Deus IA, Santos SC, Cust\u00f3dio CA, Mano JF. Designing highly customizable human-based platforms for cell culture using proteins from the amniotic membrane. Biomaterials Adv. 2022;134:112574. https:\/\/doi.org\/10.1016\/j.msec.2021.112574.","journal-title":"Biomaterials Adv"},{"key":"8100_CR41","unstructured":"European Medicines Agency. Scientific recommendations on classification of advanced therapy medicinal products. 2025. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/marketing-authorisation\/advanced-therapies-marketing-authorisation\/scientific-recommendations-classification-advanced-therapy-medicinal-products"},{"key":"8100_CR42","unstructured":"European Medicines Agency. IRIS public register. 2025. https:\/\/iris.ema.europa.eu\/odpublicregister\/"},{"key":"8100_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2019.01.010","author":"G Detela","year":"2019","unstructured":"Detela G, Lodge A. EU regulatory pathways for ATMPs: Standard, accelerated and adaptive pathways to marketing authorization. Cell Rep Med. 2019. https:\/\/doi.org\/10.1016\/j.omtm.2019.01.010.","journal-title":"Cell Rep Med"},{"key":"8100_CR44","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.omtm.2020.05.035","volume":"18","author":"M Elsallab","year":"2020","unstructured":"Elsallab M, Bravery CA, Kurtz A, Abou-El-Enein M. Mitigating deficiencies in evidence during regulatory assessments of advanced therapies: A comparative study with other biologicals. Mol Therapy - Methods Clin Dev. 2020;18:269\u201379. https:\/\/doi.org\/10.1016\/j.omtm.2020.05.035.","journal-title":"Mol Therapy - Methods Clin Dev"},{"issue":"11","key":"8100_CR45","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.stemcr.2022.11.019","volume":"20","author":"RA Barker","year":"2023","unstructured":"Barker RA, et al. Lessons learnt, and still to learn, in first-in-human stem cell trials. Stem Cell Rep. 2023;20(11):1234\u201345. https:\/\/doi.org\/10.1016\/j.stemcr.2022.11.019.","journal-title":"Stem Cell Rep"},{"key":"8100_CR46","unstructured":"European Medicines Agency. Annual activity report 2024. 2024. https:\/\/www.ema.europa.eu\/en\/documents\/report\/annual-activity-report-2024_en.pdf."},{"issue":"1","key":"8100_CR47","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1089\/ten.teb.2022.0094","volume":"29","author":"K Joyce","year":"2023","unstructured":"Joyce K, Buljovcic Z, Rosic G, Kaszkin-Bettag M, Pandit A. Issues with tissues: Trends in tissue-engineered products in clinical trials in the European Union. Tissue Eng Part B: Reviews. 2023;29(1):94\u2013105. https:\/\/doi.org\/10.1089\/ten.teb.2022.0094.","journal-title":"Tissue Eng Part B: Reviews"},{"key":"8100_CR48","unstructured":"European Medicines Agency. Guidelines relevant for advanced therapy medicinal products. 2025. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/advanced-therapy-medicinal-products-overview\/guidelines-relevant-advanced-therapy-medicinal-products."},{"key":"8100_CR49","unstructured":"International Council for Harmonisation. The Common Technical Document (CTD): Triangle color proofread. 2021. https:\/\/admin.ich.org\/sites\/default\/files\/2021-02\/CTD_triangle_color_Proofread.pdf."},{"key":"8100_CR50","unstructured":"European Commission. EudraLex. 2025;4. https:\/\/health.ec.europa.eu\/medicinal-products\/eudralex\/eudralex-volume-4_en."},{"key":"8100_CR51","unstructured":"European Medicines Agency. Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products. 2014. https:\/\/www.ema.europa.eu\/contact."},{"key":"8100_CR52","doi-asserted-by":"publisher","first-page":"1186224","DOI":"10.3389\/fimmu.2023.1186224","volume":"14","author":"C Capelli","year":"2023","unstructured":"Capelli C, et al. Potency assays and biomarkers for cell-based advanced therapy medicinal products. Front Immunol. 2023;14:1186224. https:\/\/doi.org\/10.3389\/fimmu.2023.1186224.","journal-title":"Front Immunol"},{"key":"8100_CR53","unstructured":"European Medicines Agency. Potency testing of cell-based immunotherapy medicinal products for the treatment of cancer: Scientific guideline. 2024. https:\/\/www.ema.europa.eu\/en\/potency-testing-cell-based-immunotherapy-medicinal-products-treatment-cancer-scientific-guideline"},{"key":"8100_CR54","unstructured":"ICH. ICH Topic Q 5\u00a0C: Quality of biotechnological products: Stability testing of biotechnological\/biological products. 1996. https:\/\/www.ema.europa.eu\/en\/ich-topic-q-5-c."},{"key":"8100_CR55","unstructured":"European Pharmacopoeia. Policy on bacterial endotoxins in substances for pharmaceutical use. 2014."},{"key":"8100_CR56","doi-asserted-by":"publisher","first-page":"105631","DOI":"10.1016\/j.yrtph.2024.105631","volume":"150","author":"HT Chien","year":"2024","unstructured":"Chien HT, et al. A roadmap towards a human-centric safety assessment of advanced therapy medicinal products. Regul Toxicol Pharmacol. 2024;150:105631. https:\/\/doi.org\/10.1016\/j.yrtph.2024.105631.","journal-title":"Regul Toxicol Pharmacol"},{"key":"8100_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-031-34567-8_1","volume":"1430","author":"M Schuessler-Lenz","year":"2023","unstructured":"Schuessler-Lenz M, et al. Marketing regulatory oversight of advanced therapy medicinal products in Europe. Adv Exp Med Biol. 2023;1430:1\u201321. https:\/\/doi.org\/10.1007\/978-3-031-34567-8_1.","journal-title":"Adv Exp Med Biol"},{"key":"8100_CR58","unstructured":"European Medicines Agency & European Commission. (n.d.). Good laboratory practice (GLP) principles in relation to ATMPs."},{"key":"8100_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2023.08.001","author":"J Delgadillo","year":"2023","unstructured":"Delgadillo J, et al. A management model in blood, tissue, and cell establishments to ensure rapid and sustainable patient access to advanced therapy medicinal products in Europe. J Cytotherapy. 2023. https:\/\/doi.org\/10.1016\/j.jcyt.2023.08.001.","journal-title":"J Cytotherapy"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08100-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08100-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08100-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:50:56Z","timestamp":1781139056000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08100-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8100"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08100-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors used GenAI (e.g., ChatGPT) to assist with literature synthesis and filtering, GitHub Copilot to identify and retrieve specific data sources, and Google searches to summarize large research studies. All content was reviewed and approved by the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of AI tools"}},{"value":"The authors declare no competing interests related to this work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"757"}}